Current trends in the pharmacotherapy of diabetic retinopathy

Journal of Postgraduate Medicine

Volumn 58, Issue 2, 2012, Pages 132-139

  Kumar, B ^a   Gupta, S K ^a   Saxena, R ^b   Srivastava, S ^a  

^a UNIVERSITY OF DELHI   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti angiogenic agents; corticosteroids; diabetic retinopathy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AFLIBERCEPT; ANTIDIABETIC AGENT; ATG 3; ATORVASTATIN; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; ENALAPRIL; ETANERCEPT; FENOFIBRATE; FLUOCINOLONE ACETONIDE; HYALURONIDASE; I VATION; IBI 20089; INFLIXIMAB; INSULIN; JSM 6427; LOSARTAN; METFORMIN; NEPAFENAC; NOVA 63035; OCRIPLASMIN; OCTREOTIDE; PAZOPANIB; PEGAPTANIB; PYCNOGENOL; RANIBIZUMAB; RUBOXISTAURIN; SIMVASTATIN; TG 100801; TRAVARIS; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VEGF TRAP EYE;

ABSENCE OF SIDE EFFECTS; BLOOD PRESSURE REGULATION; CATARACT; CATARACTOGENESIS; CORTICOSTEROID THERAPY; DIABETIC HYPERTENSION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; ENDOPHTHALMITIS; GLAUCOMA; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; IMPLANT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; LASER COAGULATION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINOPATHY; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; BLINDNESS; DIABETIC RETINOPATHY; DRUG THERAPY; HUMANS; INTRAVITREAL INJECTIONS;

EID: 84863647785     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.97176     Document Type: Review

References (86)

1. Shah CA. Diabetic retinopathy: A comprehensive review. Indian J Med Sci 2008;62:500-9.
2. Zhang W, Liu H, AlShabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011;2:96-103.
3. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol 2010;21:10-9.
4. Augustin A, Loewenstein A, Kuppermann BD. Macular edema. General pathophysiology. Dev Ophthalmol 2010;47:10-26.
5. Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2011;(7):CD008081.
6. Quiram PA, Gonzales CR, Schwartz SD. Severe steroidinduced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2006;141:580-2.
7. Sakamoto T, Ishibashi T, Ogura Y, Shiraga F, Takeuchi S, Yamashita H; Japanese Retina and Vitreous Society Triamcinolone Survey Group. Survey of triamcinolonerelated noninfectious endophthalmitis. Nihon Ganka Gakkai Zasshi 2011;115:523-8.
8. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
9. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M . Intravitreal triamcinolone for refractory diabetic macular edema: Two year results of a double masked, placebo controlled, randomized clinical trial. Ophthalmology 2006;113:1533-8.
10. Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age related macular degeneration. Curr Drug Targets 2011;12:149-72.
11. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six month outcomes. Ophthalmology 2007;114:2162-7.
12. Kim JE, Pollack JS, Miller DG, Mittra RA, Spaide RF; Isis Study Group. ISIS DME: A prospective, randomized, dose escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008;28:735-40.
13. Dehghan MH, Ahmadieh H, Ramezani A, Entezari M, Anisian A. A randomized, placebo controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17.
14. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643-50.
15. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-6.
16. Yilmaz T, Weaver CD, Gallagher MJ, Cordero Coma M, Cervantes Castaneda RA, Klisovic D, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: A systematic review. Ophthalmology 2009;116:902-11, quiz 912-3.
17. Safety and tolerability study of the helical intravitreal triamcinolone implant in diabetic macular edema (STRIDE). Available from: http://www. clinicaltrails.gov/ct2/show/NCT00915837 [Last accessed on 2011 Aug 05].
18. I vation sustained drug delivery system: Intravitreal implant for drug delivery. Available from: http://www.surmodics.com/pdf/ophthalmology.pdf. [Last accessed on 2011 Aug 05].
19. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5:1039-46.
20. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv 2010;1:435-56.
21. Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011;12:347-51.
22. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17.
23. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.
24. Cortiject product information. Available from: http://www.novagali. com/en/eye therapy. [Last accessed on 2011 Aug 5].
25. Fung AE. One year safety and efficacy of an injectable, sustained delivery, liquid steroid for treatment of macular edema due to retinal vein occlusion. Paper presented at: Angiogenesis 2010; February 20, 2010; Miami, F.L.
26. Verisome product information. Available from: http://www.iconbioscience. com/Overview.html. [Last accessed on 2011 Aug 05].
27. Hariprasad SM, Callanan D, Gainey S, He YG, Warren K. Cystoid and diabetic macular edema treated with nepafanac 0.1%. J Ocul Pharmacol Ther 2007;23:585-90.
28. Ducharme E, Weinberg JM. Etanercept. Expert Opin Biol Ther 2008;8:491-502.
29. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E. The use of intravitreal etanercept in diabetic macular edema. Semin Ophthalmol 2007;22:75-9.
30. Sfikais PP, Markomichelakis N, Theodossiadis PG, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight threatening macular edema in type 2 diabetes following treatment with the anti tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-7.
31. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
32. Valiatti FB, Crispim D, Benfica C, Valiatti BB, Kramer CK, Canani LH. The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy. Arq Bras Endocrinol Metabol 2011;55:106-13.
33. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age related macular degeneration twelve week results of an uncontrolled open label clinical study. Ophthalmology 2005;112:1035-47.
34. Campa C, Harding SP. Anti VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 2011;12:173-81.
35. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short term study. Retina 2006;26:279-84.
36. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA , et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695. e1 e15.
37. Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt Erfurth U. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol 2011;89:76-81.
38. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double masked clinical trial. Eur J Ophthalmol 2008;18:263-9.
39. Rosenfeld PR, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355:1419-31.
40. Matsumiya W, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A. Early responses to intravitreal ranibizumab in typical neovascular age related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol 2011;2011:742020.
41. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12.e1.
42. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33.e1.
43. Vascular Endothelial Growth Factor (VEGF) Trap Eye: Investigation of Efficacy and Safety in Wet Age Related Macular Degeneration(AMD) (VIEW1). Available from: http://www.clinicaltrials.gov/ct2/show/NCT 00509795 term=Aflibercept+VIEW+1andrank=1 [Last accessed on 2011 Nov 21].
44. Vascular Endothelial Growth Factor (VEGF) Trap Eye: Investigation of Efficacy and Safety in Wet Age Related Macular Degeneration (AMD) (VIEW 2) Available from: http://www.clinicaltrials.gov/ct2/show/NCT 00637377 term=Aflibercept+VIEW+1andrank=2[Last accessed on 2011 Nov 21].
45. A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00536016. [Last accessed on 2011 Aug 05].
46. A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT00414999. [Last accessed on 2011 Aug 05].
47. Topical Ocular Mecamylamine in Diabetic Macular Edema (DME). Available from: http://www.clinicaltrials.gov/ct2/show/NCT0053669 2 term=COMENTISandrank= 2[Last accessed on 2011 Aug 5].
48. Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009;127:494-9.
49. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00612456 [Last accessed on 2011 Aug 05].
50. Kupperman BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for vitreous hemorrhage study groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:573-84.
51. Kupperman BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for vitreous hemorrhage study groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-97.
52. Lopez Lopez F, Rodriguez Blanco M, Gomez Ulla F, Marticorena J. Enzymatic vitreolysis. Curr Diabetes Rev 2009;5:57-62.
53. A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With DME (MIVI II). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00412451 term=MIVI IIandrank=1 [Last accessed on 2011 Aug 05].
54. Trial of Microplasmin Intravitreal Injection for Non Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI TRUST (TG MV 007) Trial. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00798 317 term=MIVI TRUST+Phase+IIIandrank=1 [Last accessed on 2011 Aug 05].
55. Trial of Microplasmin Intravitreal Injection for Non surgical Treatment of Focal Vitreomacular Adhesion. The MIVI TRUST (TG MV 006) Trial. Available from: http://clinicaltrials.gov/ct2/show term=MIVI TRUST +Phase+IIIandrank=2 [Last accessed on 2011 Aug 05].
56. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
57. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 2008;126:793-9.
58. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16:621-9.
59. Xavier DO, Amaral LS, Gomes MA, Rocha MA, Campos PR, Cota BD, et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 2010;64:220-5.
60. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomized controlled trial. Lancet 2007;370:1687-97.
61. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet 2005;366:1849-61.
62. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator activated receptor (PPAR ) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998;246:370-4.
63. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand Leroux C. Neurological recovery promoting, anti inflammatory, and anti oxidative effects afforded by fenofibrate, a PPAR agonist, in traumatic brain injury. J Neurotrauma 2007;24:1119-31.
64. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: An emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6:454-63.
65. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo controlled trial. Lancet 2004;364:685-96.
66. The ACCORD Study Group and ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
67. Vaajanen A, Lakkisto P, Virtanen I, Kankuri E, Oksala O, Vapaatalo H, et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol 2010;88:431-8.
68. Willis LM, El Remessy AB, Somanath PR, Deremer DL, Fagan SC. Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence. Clin Sci 2010;120:307-19.
69. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
70. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT Protect 2): A randomised placebo controlled trial. Lancet 2008;372:1385-93.
71. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT Prevent 1) and progression (DIRECT Protect 1) of retinopathy in type 1 diabetes: randomised, placebo controlled trials. Lancet 2008;372:1394-402.
72. Amadio M, Bucolo C, Leggio GM, Drago F, Govoni S, Pascale A. The PKCbeta/HuR/VEGF pathway in diabetic retinopathy. Biochem Pharmacol 2010;80:1230-7.
73. Gálvez MI. Protein kinase C inhibitors in the treatment of diabetic retinopathy. Review. Curr Pharm Biotechnol 2011;12:386-91.
74. PKC DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty month results of the randomized PKC DMES clinical trial. Arch Ophthalmol 2007;125:318-24.
75. Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, et al. Effect of ruboxistaurin on the visual acuity decline associated with long standing diabetic macular edema. Invest Ophthalmol Vis Sci 2009;50:1-4.
76. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care 2000;23:504-9.
77. Shah SM, Nguyen QD, Mir HS, Polito A, Hafiz G, Tatlipinar S, et al. A randomized, double masked controlled clinical trial of Sandostatin long acting release depot in patients with post surgical cystoid macular edema. Retina 2010;30:160-6.
78. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989;38:491-8.
79. The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990;108:1577-83.
80. Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti inflammatory mechanisms. J Ocul Pharmacol Ther 2011;27:123-30.
81. Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, et al. Pycnogenol® Improves Microcirculation, Retinal Edema, and Visual Acuity in Early Diabetic Retinopathy. J Ocul Pharmacol Ther 2009;25:537-40.
82. Spadea L, Balestrazzi E. Treatment of vascular retinopathies with Pycnogenol. Phytother Res 2001;15:219-23.
83. Nakajima M, Cooney MJ, Tu AH, Chang KY, Cao J, Ando A, et al. Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest Ophthalmol Vis Sci 2001;42:2110-4.
84. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999;398:381.
85. Kumar B, Gupta SK, Nag TC, Srivastava S, Saxena R. Green tea prevents hyperglycemia induced retinal oxidative stress and inflammation in streptozotocin induced diabetic rats. Ophthalmic Res 2012;47:103-08.
86. Kumar B. Hesperetin protects diabetic retinopathy through its antioxidant, anti inflammatory and anti angiogenic pathways in streptozotocin induced diabetic rats. Paper presented at: Apaosydney2011, 2011 mar 20-24;Sydney, Australia, p. 174.